Imatinib mesylate (STI571) in patients with chronic myeloid leukemia in chronic phase previously submitted to autologous stem cell transplantation.

被引：0
|
作者：
Cervantes, F
Hernández-Boluda, JC
Odriozola, J
Camós, M
Villalón, L
Martínez-Climent, JA
del Campo, R
García-Conde, J
Montserrat, E
机构：
[1] IDIBAPS, Hosp Clin, Dept Hematol, Barcelona, Spain
[2] Hosp Clin, Dept Hematol & Oncol, Valencia, Spain
[3] Hosp Ramon y Cajal, Hematol Serv, E-28034 Madrid, Spain
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4818
引用
收藏
页码：318B / 318B
页数：1
相关论文
共 50 条
  • [21] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    K. Miyachi
    A. Ihara
    R. W. Hankins
    R. Murai
    S. Maehiro
    H. Miyashita
    Clinical Rheumatology, 2003, 22 : 329 - 332
  • [22] Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report
    Choi, IK
    Kim, BS
    Lee, KA
    Ryu, S
    Seo, HY
    Sul, H
    Choi, JG
    Sung, HJ
    Park, KH
    Yoon, SY
    Oh, SC
    Seo, JH
    Choi, CW
    Shin, SW
    Yoon, SY
    Cho, YJ
    Kim, YK
    Kim, YH
    Kim, JS
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (04) : 366 - 369
  • [23] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    Miyachi, K
    Ihara, A
    Hankins, RW
    Murai, R
    Maehiro, S
    Miyashita, H
    CLINICAL RHEUMATOLOGY, 2003, 22 (4-5) : 329 - 332
  • [24] Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia
    Gorre, ME
    Sawyers, CL
    CURRENT OPINION IN HEMATOLOGY, 2002, 9 (04) : 303 - 307
  • [25] The Effects of Genistein and STI571 (Imatinib) on Signal Protein Levels Affecting Chronic Myeloid Leukemia
    Armutcuoglu, Nur Erden
    Kasap, Yesim Korkmaz
    Yurtcu, Erkan
    GAZI MEDICAL JOURNAL, 2018, 29 (03): : 187 - 190
  • [26] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [27] STI571 (glivec) in the treatment of patients with chronic myeloid leukemia (CML) relapsing after allogeneic stem cell transplantation (allo SCT)
    Pfeifer, H
    Wassmann, B
    Scheuring, U
    Binckebanck, A
    Atta, J
    Brück, P
    Martin, H
    Bartmann, M
    Gschaidmeier, H
    Thiede, C
    Bomhäuser, M
    Hoelzer, D
    Ottmann, OG
    BONE MARROW TRANSPLANTATION, 2002, 29 : S34 - S34
  • [28] Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571)
    Dressman, MA
    Malinowski, R
    McLean, LA
    Gathmann, I
    Capdeville, R
    Hensley, M
    Polymeropoulos, MH
    CLINICAL CANCER RESEARCH, 2004, 10 (07) : 2265 - 2271
  • [29] Imatinib mesylate in the treatment of relapse of chronic myeloid leukemia after allogeneic stem sell transplantation.
    Zhu, KG
    Zhang, T
    Chen, J
    Zhong, J
    BLOOD, 2005, 106 (11) : 291B - 291B
  • [30] Lack of cytogenetic response is an adverse prognostic factor for relapse of chronic phase CML patients treated with imatinib mesylate (STI571).
    O'Dwyer, M
    Mauro, MJ
    Blasdel, C
    Farnsworth, M
    Kurilik, G
    Fong, D
    Hsieh, YC
    Mori, M
    Capdeville, R
    Druker, BJ
    BLOOD, 2001, 98 (11) : 137A - 138A
12345